PRURITUS THERAPEUTICS MARKET ANALYSIS

Market News

The increasing product launches and approvals is expected to boost global pruritus therapeutics market growth. For instance, on May 26, 2020, Sanofi, a global biopharmaceutical company dedicated to human health, announced that the U.S. Food and Drug Administration (FDA) has approved its Dupixent (dupilumab) for children between 6 to 11 years with moderate-to-severe atopic dermatitis (eczema) with pruritus as one of its major symptom. This disease in children is not adequately controlled by topical prescription therapies or those therapies that are contraindicated. Dupixent is the only biologic medicine approved for this patient population in treating eczema with pruritus.

Furthermore, rising mergers, agreements, and acquisitions by market players are expected to propel the global pruritus therapeutics market over the forecast period. For instance, on August 24, 2020, MC2 Therapeutics, a pharmaceutical company that develops topical therapies, announced a collaboration agreement with EPI Health, LLC to commercialize WYNZORA Cream in the U.S. EPI Health is a leading pharmaceutical company in dermatology community. WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20, 2020) for the topical treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.